Seoul National University Bundang Hospital (SNUBH), CurePSP and GemVax & KAEL have signed a tripartite memorandum of understanding (MOU) to establish Korea's first international progressive supranuclear palsy (PSP) research and treatment centre.

This initiative aims to propel research and treatment for PSP and related neurological conditions, addressing the challenges of an ageing population.

SNUBH president and CEO Dr Junghan Song said: "The establishment of the International PSP Research and Treatment Centre is expected to serve as a significant turning point in providing practical support to patients with rare and intractable diseases.

“SNUBH will make every effort to play a leading role in research and treatment development to overcome neurodegenerative diseases, building on the collaboration with CurePSP and GemVax."

The centre is set to become a hub for research, education, and treatment, integrating the resources and expertise of SNUBH, CurePSP, and GemVax & KAEL.

It will also focus on the commercialisation of new therapies, aiming to make contributions to public welfare, with an emphasis on aiding socially marginalised groups.

SNUBH professor Sanghoon Jheon said: "SNUBH is dedicated to advancing global standards in education, research, and medical care, ensuring that humanity can enjoy healthier and happier lives.

“The International PSP Research and Treatment Centre will focus its efforts on becoming an international hub for fostering exceptional professionals and advancing research to conquer rare and intractable diseases."

The new centre will leverage SNUBH's capabilities to ensure its stable operation and lead advancements in education, medical care, and research.

US-based nonprofit organisation CurePSP will provide expert advice and guidance on best practices for PSP care and research.

GemVax & KAEL will play a role in funding the establishment of the centre and drive the research, development, and commercialisation of therapeutics for PSP.